By Fineline Cube ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership with West China Hospital. The collaboration aims to work together on medical research and product transformation in the area of “chronic kidney disease (CKD) sodium restriction digital therapy.” This partnership marks a significant step in addressing the high sodium risk in the CKD population through evidence-based medicine.
Product Innovation and Target Population
The product, the first of its kind designed to lower the high sodium risk in the CKD population, is based on evidence-based medicine for household use. It targets a significant health issue, as up to 125 million people in China suffer from CKD, a disease with a high incident rate closely linked to unhealthy lifestyles. The therapy is particularly relevant given the impact of an unhealthy diet and a sedentary lifestyle on CKD, necessitating lifestyle interventions.
Collaboration and Research Focus
Through this partnership, ThinmedTech and West China Hospital will focus on developing and implementing digital therapies that can effectively manage CKD. The collaboration will leverage the expertise of both entities to create innovative solutions that can be used in household settings, making it more accessible to patients. The goal is to improve the quality of life for patients with CKD by managing their sodium intake and promoting healthier lifestyles.-Fineline Info & Tech